AURO LABORATORIES LTD.

Auro Laboratories Limited has announced the closure of its trading window for dealing in the company's securities. This closure is effective from July 01, 2026, and applies to all connected/designated persons and their immediate relatives. The purpose of this measure is to facilitate the consideration of the un-audited financial results for the quarter ended June 30, 2026. The trading window is set to reopen 48 hours after the aforementioned financial results are made generally available to the public. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Auro Laboratories Ltd has appointed Nitesh Bohra as Chief Financial Officer, effective May 29, 2026. The company also appointed B.L. Dasharda & Associates as Tax Auditors and Kuntal Pancholi as Internal Auditor for FY 2026-27. Additionally, Poddar & Co. has been re-appointed as Cost Auditors for FY 2026-27. The board approved the audited financial results for the quarter and year ended March 31, 2026.

Auro Laboratories Ltd has announced its financial results for the year ended March 31, 2026. The board approved the appointment of Mr. Nitesh Bohra as CFO and Key Managerial Personnel, M/s. B.L. Dasharda & Associates as Tax Auditors, Mr. Kuntal Pancholi as Internal Auditor, and the re-appointment of M/s. Poddar & Co. as Cost Auditors for FY 2026-27. The board also approved the audited financial results for the quarter and year ended March 31, 2026.

Auro Laboratories Ltd has appointed Mr. Nitesh Bohra as Chief Financial Officer and Key Managerial Personnel effective May 29, 2026. The company also appointed M/s. B.L. Dasharda & Associates as Tax Auditors and Mr. Kuntal Pancholi as Internal Auditor for FY 2026-27. Additionally, M/s. Poddar & Co. were re-appointed as Cost Auditors for FY 2026-27. The Board approved the audited financial results for the quarter and year ended March 31, 2026.

Auro Laboratories Limited announced the resignation of Mr. Kuntal Pancholi from his position as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP). The resignation is effective from the close of business hours on May 28, 2026. Mr. Pancholi cited personal reasons for his departure and confirmed there are no other material reasons for his resignation. Consequently, he will cease to be a KMP under the Companies Act, 2013, from the same date. The company has taken this information on record and provided the necessary disclosure under SEBI (LODR) Regulations, 2015.

Auro Laboratories Ltd has scheduled a Board of Directors meeting on May 29, 2026, to consider and approve the Audited Financial Results for the quarter and year ended March 31, 2026. The trading window has been closed from April 1, 2026, and will reopen 48 hours after the announcement of the financial results.

Auro Laboratories Ltd. has received an 'Attestation of Inspection' from the European Directorate for the Quality of Medicines & Healthcare (EDQM) for its manufacturing facility at MIDC Tarapur, Maharashtra. The attestation, referencing inspection number INSP 2012-002-P05, confirms compliance with Good Manufacturing Practice (GMP) requirements under EU Rules for CEP Dossier No. CEP 2005-123 /Metformin Hydrochloride.

Auro Laboratories Ltd has announced the closure of its trading window for all connected/designated persons and their immediate relatives. This closure is in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015. The closure is effective from April 01, 2026, and is for the purpose of considering the Audited Financial Results for the Quarter and year ended March 31, 2026. The trading window will reopen 48 hours after the Audited Financial Results become generally available.

Auro Laboratories Limited has announced its financial results for the quarter ended December 31, 2025. The company's Board of Directors approved the unaudited financial results in a meeting on February 05, 2026. The results will be published in newspapers and will be available on the company's and stock exchange's websites. The company operates in the Pharmaceuticals segment and has provided a gratuity provision of Rs 1.06 lakhs in accordance with the New Labour Codes.

Auro Laboratories Limited has submitted the Financial Results for the Quarter Ended December 31, 2025. The Board of Directors approved the Unaudited Financial Results for the quarter ended December 31, 2025, which will be published in newspapers and made available on the company’s and stock exchange websites. The company operates in the Pharmaceuticals segment and has provided a gratuity provision of Rs 1.06 lakhs in accordance with the New Labour Codes.